# **Continuing Education Credit Information**

#### **Course Description**

This one-day symposium will provide a comprehensive update on recent advances in the care of patients with thoracic malignancies. There is increasing recognition of a gap between evidence-based guidelines and clinical practice, with research demonstrating that up to 40% of patients fail to receive effective therapies and 20% of patients receive therapies that are ineffective or even harmful. Reducing these gaps leads to reduction in patient morbidity and mortality, and decreased health care costs. With the rapid advances in thoracic oncology, this symposium attempts to crystallize current knowledge and provide critical information and key take-home points to the busy practicing clinician involved in the care of patients with thoracic malignancies. Key focus topics will include guidelines to establish an effective clinically oriented smoking cessation program, the changes to lung cancer staging using the IASLC 8th edition guidelines, novel diagnostic tools such as robotic bronchoscopy, patient selection for multi-modality therapy in locally advanced lung cancer including surgical controversies and role of immunotherapy and proton beam radiation, advances in the biology and management of small cell lung cancer, and recent advances in immuno-oncology and targeted therapies in lung cancer. The symposium will also focus on strategies to detect and manage toxicities of immunotherapy for nurses and pharmacists. This symposium will review all of the recent advances in a highly interactive case-based discussion format, supported by didactic lectures by thought leaders and other well-respected faculty in each field.

#### Learning Objectives

#### Physicians

- Determine strategies to establish an effective evidencebased clinical smoking cessation program
- Apply the 8th edition of the IASLC staging system and utilize appropriate staging modalities to arrive at the correct stage to guide evidence-based treatment options
- Critique the use of novel diagnostic tools such as robotic bronchoscopy
- Debate the controversies surrounding clinical decision making in locally advanced lung cancer including the role of surgery, proton beam radiation and immunotherapy
- Explain the evolving data pertaining to immunooncology in lung cancer with emphasis on appropriate sequencing/combination with chemotherapy and the role of potential biomarkers for immunotherapy
- Discuss recent progress and future directions in the development of targeted therapies for lung cancer, in common and uncommon oncogenic mutation driven lung cancer
- Evaluate the latest advances in the biology and management of small cell lung cancer

#### Nurses

- Discuss nursing strategies for early detection of immunemediated toxicities
- Recognize common immune related adverse effects and factors that increase patient's risk of developing immune-related adverse effects

#### **Target Audience**

This conference is intended for pulmonologists, medical and radiation oncologists, pathologists, radiologists including nuclear medicine physicians and interventional radiologists, thoracic surgeons, residents, fellows, medical students, nurses, nurse practitioners, physician assistants, pharmacists, and other members of the healthcare team interested in diagnosis and treatment of lung cancer.

#### Accreditation



MedStar Health is jointly accredited by the Accreditation Council for Continuing DINTLY ACCREDITED PROVIDER Medical Education (ACCME), the

Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC) and the American Academy of PAs (AAPA) to provide continuing education for the healthcare team.

#### **Credit Designation**



This activity was planned by and for the healthcare team, and learners will receive 6.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

# Future Directions Progress and Washington D.C. $\ddot{\infty}$ Wink Hotel 20 The Cer \_\_\_\_ 8, 2018 an December Jung

NW, Sui 20008 MedStar Health 3007 Tilden St., N Washington, DC 3




Georgetown / Hospital omprehensive





Cancer Center

# Lung Cancer 2018: Progress and Future Directions



# **December 8, 2018** The Wink Hotel | Washington D.C.

# **Course Directors**

### Deepa S. Subramaniam, MD, MSc

Georgetown Lombardi Comprehensive Cancer Center MedStar Georgetown University Hospital Washington, D.C.

# Giuseppe Giaccone, MD, PhD

Georgetown Lombardi Comprehensive Cancer Center MedStar Georgetown University Hospital MedStar Georgetown Cancer Institute Washington, D.C.

MedStar Georgetown University Hospital Lombardi Comprehensive

# **Course Directors**

#### Deepa S. Subramaniam, MD, MSc

Director, Brain Tumor Center Director, Multidisciplinary Thoracic Oncology Clinic Georgetown Lombardi Comprehensive Cancer Center MedStar Georgetown University Hospital Associate Professor, Medicine Georgetown University Medical Center Washington, D.C.

# **Planning Committee**

#### Chul Kim, MD, MPH

Thoracic Medical Oncologist MedStar Georgetown University Hospital MedStar Washington Hospital Center Assistant Professor, Medicine Georgetown University Medical Center Washington, D.C.

# Faculty

#### Eric D. Anderson, MD

Director, Interventional Pulmonology MedStar Georgetown University Hospital Professor, Clinical Medicine Pulmonary, Critical Care and Sleep Medicine Georgetown University Medical Center Washington, D.C.

#### Joshua Bauml, MD

Assistant Professor, Hematology/Oncology Perelman School of Medicine University of Pennsylvania Philadelphia, PA

#### Anna F. Farago, MD, PhD

Physician Center for Thoracic Cancers at Massachusetts General Hospital Instructor, Medicine Harvard Medical School Boston, MA

#### Ganesh Krishna, MD

Interventional Pulmonologist Palo Alto Medical Foundation Program Director Interventional Pulmonary Program Professor, Medicine University of California, San Francisco San Francisco, CA

#### Giuseppe Giaccone, MD, PhD

Associate Director, Clinical Research Georgetown Lombardi Comprehensive Cancer Center MedStar Georgetown University Hospital Director, Clinical Research MedStar Georgetown Cancer Institute Professor, Medical Oncology and Pharmacology Georgetown University Medical Center Washington, D.C.

#### Ama O. Marfo, PharmD

Clinical Pharmacy Specialist Hematology/Oncology MedStar Georgetown University Hospital Washington, D.C.

#### Jillian E. Thompson, MSN, AOCNP

**Nurse Practitioner** Georgetown Lombardi Comprehensive Cancer Center MedStar Georgetown University Hospital Washington, D.C.

#### Jonathan W. Lischalk, MD

Radiation Oncologist MedStar Georgetown University Hospital Clinical Instructor, Radiation Medicine Georgetown University Medical Center Washington, D.C.

#### Stephen V. Liu, MD

Thoracic Medical Oncologist Georgetown Lombardi Comprehensive Cancer Center MedStar Georgetown University Hospital Assistant Professor, Medicine Georgetown University Medical Center Washington, D.C.

#### **Brendon M. Stiles, MD**

Thoracic Surgeon New York-Presbyterian Hospital Associate Professor, Cardiothoracic Surgery Weill Cornell Medical College New York, NY

#### Kathryn L. Taylor, PhD

Professor, Oncology Cancer Prevention and Control Program Georgetown Lombardi Comprehensive Cancer Center Georgetown University Medical Center Washington, D.C.

# Agend

	7:00 a.m.	Registration and Breakfast	SESSION III: TACTICAL TARGETS - / PROGRESS?	
	8:00 a.m.	Welcome Remarks Deepa S. Subramaniam, MD, MSc		ephen V. Liu, MD
	h S		11:10 a.m.	Case Presentation
E.		F SMOKES, SCREENS AND STAGES hul Kim, MD, MPH	11:20 a.m.	<b>Advances in Sma</b> Anna F. Farago, MD,
	8:10 a.m.	Case Presentation	11:40 a.m.	Update on Target
	8:20 a.m.	Smoking Cessation Program Implementation		<b>Cancer</b> Deepa S. Subraman
		Kathryn L. Taylor, PhD	12:00 p.m.	Novel Targets in I Giuseppe Giaccone,
	8:40 a.m.	The Use of ctDNA in the Management of Non-Small Cell Lung Cancer Joshua Bauml, MD	12:20 p.m.	<b>Panel Discussion</b> Moderator: Stepher Panelists: A. Farago,
	9:00 a.m.	IASLC 8th Edition Guidelines Eric D. Anderson, MD		D. Subramaniam
	9.20 a.m.	<b>Panel Discussion</b> Moderator: Chul Kim, MD, MPH Panelists: E. Anderson, J. Bauml, K. Taylor		Lunch and Visit t
	9:30 a.m.	Break and Visit the Exhibits	Moderator: Gi	useppe Giaccone, MD, I
	SESSION II:	MULTI-DISCIPLINARY MANAGEMENT OF	1:30 p.m.	Case Presentation
		VANCED NSLC eepa S. Subramaniam, MD, MSc	1:40 p.m.	Chemo-IO Combi NSCLC Stephen V. Liu, MD
	9:50 a.m.	Case Presentation	2:00 p.m.	Nursing and Pha in the Manageme
	10:00 a.m.	Advances in Peripheral Lung Access Ganesh Krishna, MD		Ama O. Marfo, Phari Jillian E. Thompson,
	10:20 a.m.	Proton Beam Radiation Therapy in Lung Cancer Jonathan W. Lischalk, MD	2:30 p.m.	Chemo-IO Combi Stage/Locally Adv Chul Kim, MD, MPH
	10:40 a.m.	Surgical Controversies in the Management of Locally Advanced NSCLC Brendon M. Stiles, MD	2:50 p.m.	<b>Q&amp;A Panel Discus</b> Moderator: Giusepp Panelists: C. Kim, S. J. Thompson
	11:00 a.m.	<b>Panel Discussion</b> Moderator: Deepa S. Subramaniam, MD, MSc Panelists: G. Krishna, J. Lischalk, B. Stiles	3:00 p.m.	<b>Closing Remarks</b> Giuseppe Giaccone,
		desta		

# **Registration Information**

RE WE MAKING	Reg				
	Phy				
	Res				
	Nu				
I Cell Lung Cancer PhD	Nu				
	Phy				
ed Therapies in Lung	Pha				
am, MD, MSc					
ung Cancer					

V. Liu, MD G. Giaccone,

Lung Cancer

MD, PhD

e Exhibits

**OTHERAPY** 

nations in Advanced

rmacy Perspectives nt of IO Toxicities MSN, AOCNP

nations in Early vanced NSCLC

sion Giaccone, MD, PhD Liu, A. Marfo,

MD, PhD

gistration Fees:	Now - December 6	On-Site
ysician	\$175	\$200
sident or Fellow	\$100	\$75
rse Practitioner	\$100	\$125
rse	\$100	\$125
ysician Assistant	\$100	\$125
armacist	\$100	\$125
ied Health Professional	\$100	\$125

#### **Online Registration Preferred**

Please visit our secure website at **CE.MedStarHealth.org/LungCancer** for updated program and registration information. We are unable to accept registrations or cancellations by telephone. If you wish to pay your registration fee by check, please download and print a registration form and mail it to the address on the registration form with your check.

All registrations will be confirmed by email only. Please use an email address that you check regularly. If you have guestions regarding registration or do not receive an email confirmation of your registration within 1-2 business days, please contact us at medstarcme@gmail.com or 202-780-1655.

#### **Cancellation Policy**

Cancellations made in writing by October 26, 2018 will be subject to a 50% penalty. No refunds will be given after October 26, 2018. Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, MedStar Health will refund the registration fee, but is not responsible for any travel costs.

Please call 202-780-1655 or email medstarcme@gmail.com if you have any questions or need any additional information.

# **Venue Information**

#### The Wink

1143 New Hampshire Ave, NW Washington, D.C. 20037 TheWinkHotelDC.com 833-334-9465

#### Room Block

A block of rooms have been reserved for this conference at The Wink at the discounted rate of **\$129 per night** (plus tax). To reserve your room at this discounted rate, go to http://bookings.ihotelier.com/bookings. jsp?groupID=2288250&hoteIID=103690 or call 202-775-0800 and state that you are part of the MedStar Lung Cancer Meeting by November 8, 2018.



#### **Special Assistance**

MedStar Health wishes to ensure that no individual with a disability is excluded, denied services, segregated or otherwise treated differently from other individuals because of the absence of auxiliary aids or services identified in the Americans with Disabilities Act. Please contact 202-780-1655 to notify us of your needs.